WaveMan
WaveMan · Company
PLX · Protalix Biotherapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PLX Protalix BioTherapeutics (PLX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001006281
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
57
13F, latest reported quarter

Protalix BioTherapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Protalix BioTherapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Bashan Dror
PRESIDENT AND CEO
BUY
2025-12-23 SECtraded 2025-12-19
56,000
$101.4K
+44.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Oct 19, 2023.
  • -7.9% median (-7.9% mean) 90-day return after 2 previous buys.
  • The trade is 29.7% of the 188,516 shares held after it.
  • No other insider bought within 30 days.
  • 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Bashan Dror bought about $101.4K of PLX on Dec 19, 2025; 57 funds added in the latest 13F quarter.
Bar-Shalev Amos
Director
SELL
2025-11-19 SECtraded 2025-11-18
168
$314
+46.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • No other insider sold within 30 days.
  • 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bar-Shalev Amos sold about $314 of PLX on Nov 18, 2025, the largest insider sale at the company on our record; 57 funds added in the latest 13F quarter.
Schwartz Aharon
Director
BUY
2025-08-12 SECtraded 2025-06-10
129,000
$206.4K
+58.4%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jan 3, 2023.
  • The trade is 42.6% of the 303,000 shares held after it.
  • No other insider bought within 30 days.
  • 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schwartz Aharon bought about $206.4K of PLX on Jun 10, 2025, the largest insider purchase at the company on our record; 57 funds added in the latest 13F quarter.
Bashan Dror
PRESIDENT AND CEO
BUY
2023-10-20 SECtraded 2023-10-19
16,129
$22.7K
+73.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Apr 11, 2022.
  • The trade is 12.2% of the 132,516 shares held after it.
  • No other insider bought within 30 days.
  • 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Bashan Dror bought about $22.7K of PLX on Oct 19, 2023; 57 funds added in the latest 13F quarter.
Bashan Dror
PRESIDENT AND CEO
BUY
2023-10-20 SECtraded 2023-10-19
48,387
$67.7K
+73.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Apr 11, 2022.
  • The trade is 41.6% of the 116,387 shares held after it.
  • No other insider bought within 30 days.
  • 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PRESIDENT AND CEO Bashan Dror bought about $67.7K of PLX on Oct 19, 2023; 57 funds added in the latest 13F quarter.
7 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 2 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
57 funds bought in last quarter
more than 50% of Pharma & Biotech
Revenue
-1.2% year over year
below 58% of Pharma & Biotech
Margin
-12.5% net margin
more than 63% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
3.9% of the float short (float per yahoo 2026-10-26) · 4.3 days to cover · settled 2026-09-30
below 55% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PLX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+12.3%12M
-26%-5%+17%+39%2025-102025-122026-022026-042026-062026-082026-10 2025-12-19 · Bashan Dror bought $101.4K2025-11-18 · Bar-Shalev Amos sold $314
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PLX: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
4,046,650 sh
$9.4M
RENAISSANCE TECHNOLOGIES LLC
1,096,000 sh
$2.6M
STATE STREET CORP
983,582 sh
$2.3M
GEODE CAPITAL MANAGEMENT, LLC
979,995 sh
$2.3M
NORTHERN TRUST CORP
922,340 sh
$2.1M

Congress trades in PLX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PLX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

PLX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$419.4K position · as of 2026-06-30
0.3%
Nationwide Bailard Small Cap Value Fund
$144.8K position · as of 2026-07-31
0.1%
GuideMark Small/Mid Cap Core Fund
$110.2K position · as of 2026-06-30
0.1%
Venerable US Small Cap Fund
$96.3K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$579.7K position · as of 2026-06-30
0.0%
Goldman Sachs Small Cap Growth Insights Fund
$99.6K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Bashan
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.2M
$1.5M
$604.5K
-4%
n/a
2024
$1.5M
$524.7K
$749.7K
+6%
n/a
2023
$2.7M
$3.2M
$902.7K
+30%
n/a
2022
$1.5M
$1.9M
$795.8K
-62%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 57 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PLX financials

Revenue growth
-1.2%
XBRL, annual
Net margin
-12.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$80.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+23.5%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$7.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.28x
long-term debt only, 2023-06-30 (36 months older than the period end); equity 2026-06-30
Cash flow to debt
0.49x
TTM operating cash flow over long-term debt only, 2023-06-30 (36 months older than the period end)
Return on equity
+31.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+20.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+32.4%
operating income after a 19.3% effective tax rate, over long-term debt only, 2023-06-30 (36 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+34.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
11.09x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$198.2M
market value at close 2026-10-23 on 2026-08-01 shares, plus long-term debt only, 2023-06-30 (36 months older than the period end), minus cash 2026-06-30
FCF yield
+3.7%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
0.05x
P/E over trailing EPS growth of 229%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$52.7M$53.4M$65.5M$47.6M
Operating income-$5.5M$3.9M$10.5M-$13.0M
Net income-$6.6M$2.9M$8.3M-$14.9M
EPS (diluted)-0.080.040.09-0.31
Operating cash flow-$12.0M$8.7M-$1.3M-$25.0M
Cash$14.7M$19.8M$23.6M$17.1M
Long-term debtn/an/an/a$28.2M
SEC XBRL, fiscal years, as known on 2026-10-27

PLX Stock Sonar score 5/7 axes

Find similar shapesCompare

PLX ranks highest on profitability (88th percentile) and financial health (64th), and lowest on growth (35th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
88
Inputs
  • Return on equity+31.2% · 92 pct, sector of 545
  • Return on assets+20.1% · 92 pct, sector of 691
  • Return on invested capital+32.4% · 70 pct, sector of 45
  • Return on capital employed+34.9% · 98 pct, sector of 576
Financial health
64
Inputs
  • Debt to equity0.28x · 40 pct, sector of 352
  • Cash flow to debt0.49x · 87 pct, sector of 371
Growth
35
Inputs
  • Revenue growth, YoY-1.2% · 42 pct, sector of 505
  • Backlog growth, YoY-34.3% · 28 pct, sector of 40
Institutional and government
50
Inputs
  • Funds adding, latest quarter57 · 50 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
62
Inputs
  • Short interest, % of float+3.9% · 63 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+8.4% · 62 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies